Amazon is officially in the quick commerce arena, with its service available in parts of Bengaluru. This and more in today’s ETtech Morning Dispatch.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Catapult (CAT), De Grey Mining (DEG), Emerald Resources (EMR), Physical Silver ETF (ETPMAG), Insignia Financial (IFL), ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

Litman Gregory Wealth Management LLC lowered its stake in Exxon Mobil Co. (NYSE:XOM – Free Report) by 34.5% in the 4th ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally represents a ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...